Single-agent Capecitabine as Metronomic Chemotherapy in LAHNSCC (CMHN)

NCT05044117 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

220

Enrollment

OTHER

Sponsor class

Conditions

Head and Neck Squamous Cell Carcinoma

Interventions

DRUG: Capecitabine

Sponsor

Sun Yat-sen University

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]